Q32 Bio Inc. (QTTB) reported Q4 2025 earnings of $4.58 per share. No consensus estimate was available for comparison. Total revenue was $53.7 million.
Q32 Bio Inc. is a clinical-stage biotechnology company that develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases. The company’s lead candidate, Bempikibart (ADX-914), is a fully human anti-interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function.
The company is focused on treating conditions, including atopic dermatitis and alopecia areata by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post Q32 Bio Inc. (QTTB) Reports Q4 Earnings first appeared on Alphastreet.
